What is the 13F Pro Quality Score for SABS?

13F Pro ranks SAB Biotherapeutics, Inc. (SABS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SABS's current score at https://13fpro.ai/research/SABS (free sign-up required for the full ranking).

Which hedge funds own the most SABS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SABS include Vivo Capital,, Caligan Partners, PERCEPTIVE ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/SABS as soon as new 13F filings post.

Where does 13F Pro source SABS data?

All SAB Biotherapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. SAB Biotherapeutics, Inc. files with the SEC under CIK 1833214. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SABS in?

SAB Biotherapeutics, Inc. (SABS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SABS research updated on 13F Pro?

SABS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SAB Biotherapeutics, Inc.(SABS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1833214 SABS stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SABS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SAB Biotherapeutics, Inc. (SABS), a Healthcare sector company. SABS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), SAB Biotherapeutics, Inc. reports net income of $-18.9M, free cash flow of $-15.3M. Top institutional holders of SABS by reported 13-F value include Vivo Capital,, Caligan Partners, PERCEPTIVE ADVISORS, based on the most recent SEC filings. SABS trades on the Nasdaq exchange and files with the SEC under CIK 1833214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SABS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SAB Biotherapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-18.9M

Free Cash Flow

Q1 2026

$-15.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $23.9MFY23 $2.2MFY24 $1.3MFY25 $0.00

Net Income

+138.9% YoY

$13.3MFY 2025

FY22 $-18.7MFY23 $-42.2MFY24 $-34.1MFY25 $13.3M

Operating Income

-14.1% YoY

$-49.0MFY 2025

FY22 $-28.9MFY23 $-38.1MFY24 $-42.9MFY25 $-49.0M

EPS (Diluted)

-7.3% YoY

$-0.79FY 2025

FY22 $-0.09FY23 $-1.53FY24 $-0.74FY25 $-0.79

Total Assets

+291.0% YoY

$172.8MFY 2025

FY22 $50.9MFY23 $83.9MFY24 $44.2MFY25 $172.8M

Op. Cash Flow

-30.6% YoY

$-44.8MFY 2025

FY22 $-23.5MFY23 $-25.1MFY24 $-34.3MFY25 $-44.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$0.00 -100.0%	$1.3M -40.9%	$2.2M -90.6%	$23.9M -60.7%	$60.9M
Net Income	$13.3M +138.9%	$-34.1M +19.2%	$-42.2M -125.1%	$-18.7M -9.3%	$-17.1M
Operating Income	$-49.0M -14.1%	$-42.9M -12.7%	$-38.1M -31.7%	$-28.9M -115.9%	$-13.4M
EPS (Diluted)	$-0.79 -7.3%	$-0.74 +51.8%	$-1.53 -1672.6%	$-0.09 -584.1%	$-0.01
Total Assets	$172.8M +291.0%	$44.2M -47.3%	$83.9M +64.9%	$50.9M -35.9%	$79.4M
Operating Cash Flow	$-44.8M -30.6%	$-34.3M -36.5%	$-25.1M -7.1%	$-23.5M -1280.7%	$2.0M

AI Insight: SABS Financial Trends

SAB Biotherapeutics remains pre-revenue with equity volatility masking persistent operating cash burn.

• Revenue stayed at or near $0M across all eight quarters; single $1M quarter in Q1 2025 was exception.

• Operating cash flow negative in all periods; Q1 2026 burn rate of $-14M unchanged from prior year baseline.

• Equity swung sharply from $12M (Q2 2025) to $227M (Q1 2026), likely from financing, but masks no operational improvement.

⚠ Q3 2025 net income of +$45M stands out as one-time non-operating item; subsequent quarters reverted to $-17M to $-19M losses.

⚠ Operating margin contracted to $-20M (Q1 2026) from $-16M (Q4 2025); cash burn trajectory worsening into 2026.

AI Insight: SABS Ratio Trends

SABS remains unprofitable across all periods with volatile quarterly returns; no sustained path to positive earnings evident.

• ROE swung from -175.5% in Q4 2024 to +110.1% in Q3 2025, then reversed to -33.2% in Q1 2026—extreme volatility.

• ROIC deteriorated from -25.6% (TTM) to -35.2% (Q1 2026), indicating capital destruction persists despite Q3 2025 anomaly.

• ROA improved from -77.0% (Q3 2024) to -30.4% (Q1 2026), but remains deeply negative with no operating margin data.

⚠ Q3 2025's positive ROE (+110.1%) and ROA (+99.1%) appear isolated; Q4 2025 and Q1 2026 reverted to losses—underlying operations unresolved.

⚠ No OpMargin or NPM data across any period limits visibility into revenue generation or unit economics improvement.

Get alerted when SABS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SAB Biotherapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SABS

Vivo Capital, LLC
$43.7M11,420,000 sh
Caligan Partners LP
$30.5M7,967,207 sh
PERCEPTIVE ADVISORS LLC
$24.6M6,431,743 sh
Commodore Capital LP
$16.9M4,401,500 sh
RA CAPITAL MANAGEMENT, L.P.
$16.9M4,401,500 sh
BALYASNY ASSET MANAGEMENT L.P.
$14.4M3,760,439 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$13.0M3,405,553 sh
MILLENNIUM MANAGEMENT LLC
$11.6M3,032,697 sh
Woodline Partners LP
$10.9M2,851,791 sh
VANGUARD CAPITAL MANAGEMENT LLC
$9.6M2,493,737 sh

Fund	Value	Shares
Vivo Capital, LLC	$43.7M	11,420,000
Caligan Partners LP	$30.5M	7,967,207
PERCEPTIVE ADVISORS LLC	$24.6M	6,431,743
Commodore Capital LP	$16.9M	4,401,500
RA CAPITAL MANAGEMENT, L.P.	$16.9M	4,401,500
BALYASNY ASSET MANAGEMENT L.P.	$14.4M	3,760,439
ADAGE CAPITAL PARTNERS GP, L.L.C.	$13.0M	3,405,553
MILLENNIUM MANAGEMENT LLC	$11.6M	3,032,697
Woodline Partners LP	$10.9M	2,851,791
VANGUARD CAPITAL MANAGEMENT LLC	$9.6M	2,493,737

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SABS on your watchlist

Track score changes the day SAB Biotherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SABS a good stock to buy?

13F Pro's AI-powered analysis of SAB Biotherapeutics, Inc. (SABS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SABS are available on the SABS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SABS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SABS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SAB Biotherapeutics, Inc.'s investment landscape.